
vTv Therapeutics (VTVT) Stock Forecast & Price Target
vTv Therapeutics (VTVT) Analyst Ratings
Bulls say
vTv Therapeutics is a promising late-stage biopharmaceutical company with a strong focus on developing oral, small-molecule drug candidates for the treatment of chronic diseases, such as type 1 diabetes. Their lead candidate, cadisegliatin, has demonstrated positive clinical data and has received Breakthrough Therapy Designation, positioning it well for success in the Phase 3 CATT1 trial. Additionally, the company's plans to expand the use of cadisegliatin through the Hybrid CATT1 trial and its potential as a complement to emerging curative therapies, including cell therapy and gene therapy, further support a positive outlook for this stock.
Bears say
vTv Therapeutics is facing several challenges that may hinder its success in the coming years. Its current pipeline, led by cadisegliatin, is the company's main hope for commercial success, with a forecasted peak revenue of $1.6 billion. However, the company faces significant risks, including potential safety concerns, lower than expected efficacy, and intense competition in the market, which could all significantly impact its bottom line and delay its path to profitability and success. Furthermore, the company is heavily dependent on third-party suppliers for its product candidates, which could lead to delays in clinical trials and ultimately affect its ability to bring a successful product to market.
This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
vTv Therapeutics (VTVT) Analyst Forecast & Price Prediction
Start investing in vTv Therapeutics (VTVT)
Order type
Buy in
Order amount
Est. shares
0 shares